Part 6/10:
This technological leap is underpinned by the leadership and vision of OpenAI CEO Sam Altman, who has invested heavily in life extension initiatives—almost $555 million across various projects, including biotech startups. Notably, his investments include:
Retro Biosciences, a Silicon Valley biotech firm dedicated to understanding and manipulating cellular aging mechanisms.
Investment in other longevity-focused companies such as Alton Labs and support for research into anti-aging therapeutics.
Altman’s commitment underscores a belief that breakthroughs in AI-enabled biotechnologies could unlock decades of added life and significantly improve quality of life.